These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 32348223)

  • 21. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
    Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
    Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease.
    Morsy A; Trippier PC
    J Alzheimers Dis; 2019; 72(s1):S145-S176. PubMed ID: 31594236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease.
    León R; Garcia AG; Marco-Contelles J
    Med Res Rev; 2013 Jan; 33(1):139-89. PubMed ID: 21793014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Vitamin E in the Treatment of Alzheimer's Disease: Evidence from Animal Models.
    Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29168797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of TREM2 in Alzheimer's Disease and its Consequences on β- Amyloid, Tau and Neurofibrillary Tangles.
    Singh AK; Mishra G; Maurya A; Awasthi R; Kumari K; Thakur A; Rai A; Rai GK; Sharma B; Kulkarni GT; Singh SK
    Curr Alzheimer Res; 2019; 16(13):1216-1229. PubMed ID: 31481003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease.
    Kazim SF; Iqbal K
    Mol Neurodegener; 2016 Jul; 11(1):50. PubMed ID: 27400746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's pathology targets distinct memory networks in the ageing brain.
    Maass A; Berron D; Harrison TM; Adams JN; La Joie R; Baker S; Mellinger T; Bell RK; Swinnerton K; Inglis B; Rabinovici GD; Düzel E; Jagust WJ
    Brain; 2019 Aug; 142(8):2492-2509. PubMed ID: 31199481
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sigma ligands as potent inhibitors of Aβ and AβOs in neurons and promising therapeutic agents of Alzheimer's disease.
    Ma WH; Chen AF; Xie XY; Huang YS
    Neuropharmacology; 2021 Jun; 190():108342. PubMed ID: 33045243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review.
    West S; Bhugra P
    Br J Clin Pharmacol; 2015 Aug; 80(2):221-34. PubMed ID: 25753046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (-)-Oleocanthal Nutraceuticals for Alzheimer's Disease Amyloid Pathology: Novel Oral Formulations, Therapeutic, and Molecular Insights in 5xFAD Transgenic Mice Model.
    Tajmim A; Cuevas-Ocampo AK; Siddique AB; Qusa MH; King JA; Abdelwahed KS; Sonju JJ; El Sayed KA
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
    Xie Y; Tan Y; Zheng Y; Du X; Liu Q
    J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SUMO and Alzheimer's disease.
    Lee L; Sakurai M; Matsuzaki S; Arancio O; Fraser P
    Neuromolecular Med; 2013 Dec; 15(4):720-36. PubMed ID: 23979993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
    Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
    Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
    Koychev I; Hofer M; Friedman N
    J Nucl Med; 2020 Oct; 61(10):1413-1418. PubMed ID: 32764121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
    Mazumder MK; Choudhury S
    Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An update on drug treatment options of Alzheimer's disease.
    Allgaier M; Allgaier C
    Front Biosci (Landmark Ed); 2014 Jun; 19(8):1345-54. PubMed ID: 24896354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Trends in the Management of Alzheimer's Disease: Current Therapeutic Options and Drug Repurposing Approaches.
    Singh RK
    Curr Neuropharmacol; 2020; 18(9):868-882. PubMed ID: 31989900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches.
    Rüb U; Stratmann K; Heinsen H; Seidel K; Bouzrou M; Korf HW
    J Alzheimers Dis; 2017; 57(3):683-696. PubMed ID: 28269779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current Strategies and Novel Drug Approaches for Alzheimer Disease.
    Ghai R; Nagarajan K; Arora M; Grover P; Ali N; Kapoor G
    CNS Neurol Disord Drug Targets; 2020; 19(9):676-690. PubMed ID: 32679025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.